Novavax Inc.

AI Score

0

Unlock

7.92
-0.10 (-1.25%)
At close: Feb 20, 2025, 3:59 PM
7.93
0.13%
After-hours: Feb 20, 2025, 06:41 PM EST
undefined%
Bid 7.92
Market Cap 1.27B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.18
PE Ratio (ttm) -3.63
Forward PE n/a
Analyst Buy
Ask 7.93
Volume 2,532,376
Avg. Volume (20D) 3,879,464
Open 8.06
Previous Close 8.02
Day's Range 7.70 - 8.14
52-Week Range 3.81 - 23.86
Beta undefined

About NVAX

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 5, 1995
Employees 1,543
Stock Exchange NASDAQ
Ticker Symbol NVAX
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 133.59% from the latest price.

Buy 50.00%
Hold 33.33%
Sell 16.67%
Stock Forecasts

Next Earnings Release

Novavax Inc. is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+0.12%
Shares of vaccine stocks are trading lower after t... Unlock content with Pro Subscription
3 weeks ago
+2.15%
Shares of vaccine stocks are trading higher. HHS Secretary nominee Robert F. Kennedy Jr. reportedly said he is not anti-vaccine ahead of upcoming confirmation hearings.